source
- Biopharma pay report: Top-paid CSOs, CMOs of 2025Biopharma’s top scientists and doctors don’t make nearly as much as CEOs, but some still took in eight-figure pay packages in 2025. As part of our series on industry compensation, Endpoints News lo…Endpoints · 1mo ago↗ source
- Kardigan plans $320M IPO for heart drugs as Nasdaq listings gain steamParabilis Medicines' record-breaking IPO will be a tough act to follow, but a drug developer with three late-stage cardio medicines is up for the challenge. It's led by a CEO who sold ...Endpoints · 1mo ago↗ source
- J&J looks to widen Imaavy’s use; $300M backs rare disease drug launchNew data suggest Imaavy could be an effective treatment for autoimmune anemia. Elsewhere, Enliven detailed data for a Merck leukemia rival and MBX hyperparathyroidism drug hit its goal.